Similar Content3
Innovation 'Elevator Pitch':
BVI technology is an innovative and easy to use, mHealth service to determine the percentage and distribution of visceral fat using a mobile device (tablet) or a smart phone. 
Overview of Innovation:
The Body Volume Indicator (BVI) is a new measurement for healthcare and obesity. After eight years of successful and innovative validation from scientific collaborators around the world, BVI is now undergoing final testing prior to a full launch later in 2017.

Using 3D technology, BVI calculates risk factors associated with a person's body shape, by measuring weight and body fat distribution, with particular focus on the abdomen; the area associated with the greatest risk.

BVI is designed to be a long-term addition to the Body Mass Index (BMI); the current recognised standard for measurement of obesity. The intention is for the Body Volume Indicator to become a Body Volume Index by 2020, by which time sufficient data will have been collected globally. Using smartphone technology, BVI data can now be collected anywhere with web or internet access.

Body Volume, as an indicator of health, offers a potential long-term solution as a measure of individual health risk. 

BVI was developed in the West Midlands and collaborators have included Heartlands Hospital, Aston University, Mayo Clinic and the Medical Research Council. The application was patented in the US in 2012 and throughout Europe in 2015.


 
Current Status
In 2012 Select Research obtained exclusive use of the largest and most comprehensive collection of Body Composition Data (BCD) of visceral fat data from MRI scans in the world. This has been used to develop an App which will be used to scan/photograph lightly clothed patients and then comparing their BCD database to predict their body fat and visceral fat.
 
Further research and development is being undertaken with our current BVI (Body Volume Index) tool, to provide additional evidence and to validate the efficacy, and appropriateness of this BVI application in real-life environments. Through a ‘real-life’ project work with WMAHSN will provide clinical validation for the underpinning methodology, thus making potential users (Clinicians, patients & public) aware of the benefits (social and economic) of utilising the service.
 
Thus our current BVI application is to be incorporated into the existing patient pathways currently used by Health Exchange Health Trainers in the West Midlands.
 
NB: The application has been patented in the US in 2012 and throughout Europe in 2015 and covers all measurements of part body volume for healthcare from a 3D scan. Body fat is a part volume of the human body.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Visceral fat is body fat stored within the abdominal cavity around a number of important internal organs such as the liver, pancreas, and intestines often referred to as 'active fat'. This type of fat plays a potentially dangerous role in affecting how our hormones function.

Higher amounts of visceral fat are associated with increased risks of a number of health problems.  NHS healthcare costs attributed to obesity are £5.1b p.a. and set to rise by £7.1b by 2030; The cost to the UK economy is £27b p.a. Benefits through effective intervention based on accurate visceral body fat determinations are complex but undoubtedly would lead to a reduction in the burden of obesity (diabetes, heart disease, stroke, and certain cancers), by a reduction in years lost to premature mortality and disability (DALY). NICE suggests reducing obesity of 1% would save the “NHS and local authorities around £97 million per year.” Diabetes costs the NHS over £1.5m an hour or 10% of the NHS budget for England and Wales. 

The lifetime benefits of weight loss - direct £297 and indirect £2068 estimates based on 50% compliance and 25% success.  A saving to the NHS of between £1.2m and £6.9m, and the economy of between £135m and £1620m.

Select’s BVI tool App predicts the early identification body and visceral fat & estimates via a quick, simple and non-invasive scan which provides an insight and benchmark for clinicians and their patients; just by taking two photographs of a patient. 

Therefore BVI significantly contributes to the monitoring, intervention and control processes for clinicians and other health professional to apply, so that they can tackle and halt the potential for escalation into Diabetes and CHD etc.


Particular value for patients will be that they can monitor their own progress and to improvement at home. Through recognition of the scale of their own obesity and particularly any high levels of visceral fat. The early identification of visceral fat, through this simple, quick and accurate method of measuring obesity will thus take a large step towards achieving considerable saving to the NHS and the UK economy.

The proposal for delivery of BVI is under discussion with BVI data (including BMI, Waist Circumference, and Waist to Hip Ratio automatically) stored for tracking purposes on patient records via the N3 spine. Automatic data collection through BVI of current methods saves time, money and provides new informative data on body composition for future research.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Clinical Outcomes & Economic
In the West Midlands 65.7 per cent of people are carrying excess weight, along with 65.6 per cent of people in the East Midlands. Obesity costs the UK economy exceed £3 billion per year. In Birmingham, over 25% of the population are obese - the third highest rate in the UK. The high prevalence of obesity in adults within England show that national averages of over 40% of males overweight and more than 20% obese in the 16-75 year age range, while in women the averages are lower for the overweight classification but higher for obesity.
 
Nationally GPs make 97,000 annual referrals to weight watching programmes (WWP) and costs will reach £15.6m p.a. in 2017. A saving of £48.5 per patient might be made using the BVI App. With as low as 10% uptake, £0.5m could be saved, rising to £2.8m with a 60% uptake. Better management of weight issues with patients will have significant cost savings within the West Midlands.
 
This tool will support early detection of visceral fat and therefore allow a much more preventative and timely approach to supporting West Midlands Patients to make positive lifestyle change.
 
Environmental
The BVI App offers considerable environmental benefits in reducing the number of visits (road trips) to a surgery and specialist clinics. It will also allow people within remote and rural locations to engage in such activities.
 
Research
Additional R&D is being undertaken with the WMAHSN, to further ‘validate’ the efficacy, appropriateness and validity of the BVI application in real-life environments using the BVI App, which is being incorporated into the existing patient pathways.
 
Commercially
The adoption of this technology within the West Midlands and UK will also allow our company to grow and develop, not only with increasing its functions and capabilities but also in marketing this to a worldwide healthcare organisations and individuals as obesity is a major developed countries epidemic. 
 
There is also interest from other commercial organisations involved in weight management and associated healthcare which will further extent this products role and integration with people taking charge of their well being.

Trials
The BVI tool will be tested in 3 locations in the West Midlands with patients and GP Practices in Birmingham, Dudley and Solihull. Analysis of weight loss achieved over a period will be monitored.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Current and planned activity: 
Current BVI application is undergoing R&D and incorporation into existing patient pathways within the West Midlands via;
  • Patient Engagement - Face to face consultation, scanning of approximately 1000+ patients
  • Clinical Benefits - Analysis and monitoring of weight loss achieved over a defined period. Developing delivery protocols
  • Dissemination - Facilitation of BVI tool awareness raising sessions with Key Public Health and NHS Management, Clinical Teams and frontline staff
  • Training - BVI tool training to specialist clinical teams (Primary & Acute), ensuring correct use of the tool and providing feedback for use with patients
  • Data analysis – Verification/validation of App algorithms
  • Data gathering - Provision of clinically requested data – Core data profiling to gauge health outcomes and patient benefits. Establishing minimum data requirements
Required
  • Evaluation & Trials - Seeking trial interests
  • Adoption – Looking for discussions with CCG’s, Healthcare and Council Health Prevention teams   
What is the intellectual property status of your innovation?:
BVI has both BVI Patents and Trademarks approved.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not as yet implemented at scale within the WM region or elsewhere. The BVI product will be launched in the US market in March 2017 and Select Research Ltd are currently in discussions with Health Exchange and NHS Heartlands Hospital (who are collaborators on BVI development) for a possible follow on wider trial across the region for 2017.
Measures:
When the BVI app has been fully completed in terms of it’s scalability for widespread use, the trial results have been published and the launch takes place in April 2017, the success criteria will be determined by the number of users and the take up when the product is available and being used by customers.
 
Development is currently ongoing with scaling of the technical infrastructure for release on all accepted and recognised technical platforms (e.g. Google Play. App Store) in late April 2017. The success criteria will then become easily measurable by virtue of the volume of downloads achieved after launch.
Adoption target:
These will be dependent upon the outcome of the discussions with NHS Heartlands Hospital and Health Exchange as to a future extended trial.
Read more
Hide details
Innovation 'Elevator Pitch':
BVI measures body proportions and fat distribution avoiding the need for costly techniques such as MRI and CT scanning for visceral fat measurements. Funding is being sought to undertake a region wide trial prior to NHS national deployment.
Overview of Innovation:
For over 20 years, Select Research have been pioneers in 3D measurement of the human body and over the last 10 years have developed a novel method of measuring human body volume in 3D, derived from 2D images. Released initially as a Body Volume 'Indicator' or BVI, the aim, once enough data has been assembled worldwide, is for the 'indicator' to become a Body Volume 'Index' by the year 2020. The BVI technology is patented in Europe and the US and is currently being used in professional healthcare, fitness, academic research on an iOS platform with an android version scheduled to be completed by April 2018; well in advance of the requested April 2018 date for potential national deployment under the ITP award, where BVI has been shortlisted by NHS England.
The Body Volume Indicator (BVI), unlike BMI, creates a 3D image of a patient’s body, enabling body proportions and fat distribution to be accurately measured for each patient, avoiding the need for costly, intrusive and time-consuming techniques such as MRI and CT scanning for visceral fat measurements. Furthermore, this provides professionals with a more accurate measurement of patient health, which in turns leads to improved diagnosis and therefore better clinical outcomes. This produces a patient specific BVI number, developed over 10 years by Mayo Clinic, which ranges from 0-20 and is based upon the ratio of abdominal volume to total volume, relative to that person’s age, gender and ethnicity. BVI will enable NHS professionals to identify where there is increased risk to patient health, wherever BMI is currently used throughout primary and secondary care with patients.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Digital health
Benefit to NHS:
Obesity worldwide is measured today using the Body Mass Index (BMI) tool as the global health indicator for risk. Invented in 1824, the BMI tool uses just height and weight, and therefore doesn't differentiate between people with the same BMI reading who have different body shapes and weight distribution, such as people with athletic build or those with more abdominal volume. BMI was originally intended by the Belgium statistician, Adolphe Quetelet for general population measurement, so is not suitable for use anymore in the modern age where personalised medicine is the framework for healthcare delivery, and does not consider factors such as age, lifestyle or ethnicity. In addition, a recent study by J. Gómez-Ambrosi, et al found that BMI is miss-classifying up to 29% subjects with increased cardio metabolic risks, suggesting that the patient groups with the highest needs are being failed, treatment is being delayed and a significant unnecessary cost is burdening the NHS which could be avoided if body volume distribution was accurately measured. The NHS currently spend £12.4 nationally on data collection. BMI is used today in healthcare not out of choice, but by default, as no viable alternative has been available; BVI now provides the NHS with a unique opportunity to innovate and change.
The Body Volume Indicator (BVI), unlike BMI, creates a 3D image of a patient’s body, enabling body proportions and fat distribution to be accurately measured for each patient, avoiding the need for costly, intrusive and time-consuming techniques such as MRI and CT scanning for visceral fat measurements. Furthermore, this provides professionals with a more accurate measurement of patient health, which in turns leads to improved diagnosis and therefore better clinical outcomes. This produces a patient specific BVI number, developed over 10 years by Mayo Clinic, which ranges from 0-20 and is based upon the ratio of abdominal volume to total volume, relative to that person’s age, gender and ethnicity. BVI will enable NHS professionals to identify where there is increased risk to patient health, wherever BMI is currently used throughout primary and secondary care with patients.
BVI Pro has successfully passed the review stages of the NHS ITP programme and is now with Simon Stevens, CEO of NHS England for review. Confirmation is expected in February 2018.
 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In the West Midlands almost seven out of every 10 people are overweight or obese, whilst 81 per cent are unaware about the link with cancer. Health chiefs have warned Birmingham could be forced to spend more than £2 billion EVERY YEAR to tackle a growing obesity crisis unless urgent action is taken.
Dr Andrew Coward, chairman of Birmingham’s Childhood Obesity Steering Group, said the link between obesity and cancer is now as serious as the cancer and smoking links of the past. The GP made the striking comparison as it emerged obesity will cost the city £2.6 billion a year by 2050 if something isn’t done to tackle the problem. In the West Midlands almost seven out of every 10 people are overweight or obese, whilst 81 per cent are unaware about the link with cancer.
The easy use of the BVI Pro app means patients can conveniently measure themselves at home or in as part of a health check at a GP surgery, negating the need for invasive manual measurements to be taken.. With NHS choices currently receiving 1.5 million visitors a day, BVI Pro could be incorporated, leading to more patients able to measure their BVI, reducing time spent with healthcare professionals; enabling patients to take a more active role in managing their healthcare.

BVI Pro could provide part of an online NHS system, through which patients could access other healthcare apps, health records, and book appointments, providing patients with convenient access to their BVI data, using the unique Patient NHS Number. This would produce a more comprehensive NHS service on obesity data for policy and prevention programmes. 
The app creates a 3D patient avatar, enabling parametric measurements. Patients have been shown to be more motivated to treatment plans when presented with their own ‘avatar’ (Boelcart et al. 2008.) Leading to an improvement in lifestyle management, resulting in a reduction in cost to the NHS. Once two patient images are captured, BVI and fat distribution can be measured in less than 30 seconds. These results can be integrated with medical records, via the BT enabled N3 ‘spine’ network, providing doctors with a holistic and unparalleled databank for patient health.


 
Current and planned activity: 
BVI has been through 4 stages of the NHS England Innovation Technology Payment programme and is in review with Simon Stevens with a view to being phased in, starting with one area of the country before rolling out.
We are looking at fast track access to the NHS through The Academic Health Science Network and have applied for a H2020 grant to roll out BVI across Europe. AHSN have recommended BVI for deployment. We are awaiting confirmation. See attachments.
Most of the validations have been undertaken by The Mayo Clinic and the University of Westminster. We are requiring more data on a wider range of ethnic origins and the West Midlands is a perfect place to start as it has such a diverse population.

 
What is the intellectual property status of your innovation?:
The BVI technology is patented in Europe (EP1993443 B1) and the US (US8374671 B2) and is currently being used in professional healthcare, fitness, academic research on an iOS platform with an android version scheduled to be completed by January 2018.
 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Innovation 'Elevator Pitch':
Protect people with dementia from unattended falls, dehydration, malnutrition and hypothermia by hourly checking patterns of normal activities in their kitchens. 
Overview of Innovation:
Many older people want to live independently for as long as possible, causing anxiety for family and friends.  They are often in denial of their declining capacity, proud and won’t wear pendants.  With impaired cognition, many suffer from unattended falls, dehydration, malnutrition or hypothermia.  They are admitted to hospital needing longer treatment for poorer health outcomes and greater risk of transfer into a care home. 

To make sure that service users are moving around as normal, drinking, eating and warm, Kemuri checks every hour.  It alerts families and carers of important changes and provides valuable details for guiding action.  Peace of mind results in better outcomes and reduced costs for everybody.

Kemuri does not stigmatise because it looks a familiar Power Socket to the service user.  There’s nothing to remember and people continue with normal activities such as boiling kettles and heating food in microwaves or other electrical equipment.


KemuriSense® mains Smart Power Sockets continuously monitor motion, power usage, temperature and humidity and send data via GSM mobile phone signals to the Internet.  Mains power loss is automatically reported whilst it continues to report other sensor readings.  

The Wellbeing Monitor App informs families and carers of older vulnerable people who:
  • Want to live independently
  • Reject or forget pendant alarms
  • Deny declining capacity
  • Show symptoms of dementia
  • Remove things they don’t understand
  • Need daily monitoring 


Predictive analytics check every hour for changes to patterns of motion and power usage.  If there are many changes, then alerts may be sent to families, carers or 24/7 response centres.

As stated by a Commissioning Manager at a County Council, “ ... this is a unique product ….  I think there’s potential here for both self funder and LA funding as a potential option that fills a gap that conventional telecare does not.”
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health
Benefit to NHS:
Dementia is increasing in the population. Kemuri is a tool for stabilising the wellbeing of older people living alone who are declining in their ability to undertake Activities of Daily Living. Better wellbeing means healthier people, better health outcomes & more efficient use of NHS resources. Institute of Ageing research shows a range of pathways that people take before they are unable to live independently.


Early intervention is proven to reduce costs significantly. Kemuri should be deployed as soon as people are showing early symptoms of dementia. With loss in mobility, falls are inevitable: half those 80+ fall at least once p.a. Falls cost the NHS £2bn p.a. People with dementia tend to forget their pendant alarms/wearable telecare devices. If unable to call for help they may suffer for days before discovery & admission to A&E with medical complications. Kemuri’s hourly analysis of patterns of motion power usage automatically alerts to the risk of unattended falls.

In comparison pendant alarms are ineffective with early stage dementia. Out of 1.6m issued 32% are never worn & only 8% are worn all the time as prescribed. 500,000 unworn pendant alarms waste as much as £80m p.a. Kemuri continuously monitors motion, learns patterns of activity without any cognitive input from the service user.


A value to the NHS of early A&E admission into hospital is better health outcomes & more people discharged back to independent living on average after 12.3 days (discharge to residential care on average 31.7 days, 2.5 times longer).



£5000 could be re-allocated for each episode avoiding discharge to a care home. Unattended falls longer than 24 hours result in stabilisation time, longer treatment & delayed transfers of care. Kemuri preventive telecare with a wellbeing monitor & daily attention will also help to minimise the number of patients suffering the effects of hypothermia, dehydration & malnutrition.
  • Cold homes cost the NHS in England more than £1.36bn p.a.
  • Dehydration complications include low blood pressure, weakness, dizziness, increased risk of falls, & pressure sores
  • Malnutrition costs the NHS £7bn p.a. Risk (in 2010) was 28% in patients < 60 years, 32% 60-79 years & 44% if > 80 years
Kemuri could be funded by the NHS for a few weeks after discharge on the grounds that people admitted in a healthier state are less complex to treat, have improved health outcomes & are less likely to be readmitted, with the ongoing service funded by Social Services or self-funders.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
West Midlands has a population of 5.6 million people covering an area of more than 5,000 square miles.  It is a region full of contrasts and diversity.  It includes the second largest urban area in the country (Birmingham, Solihull and the Black Country) yet over 80% of the area is rural.  It is the second most ethnically diverse region in the country after London.  There are probably 40,000 older people who might be suitable for passive wellbeing monitoring.  Many of these are admitted to hospital and may not be able to return to their own homes. 

Older people are at the focus of Kemuri wellbeing monitoring.  Hourly and daily pattern analysis reduces risk and extends the period that they can continue to live independently at home.  Everybody has access to information that reduces the risk of unattended falls, dehydration, malnutrition and hypothermia.  Alerts are automatic without older people having to change their life style.  A familiar power socket is not stigmatising or intrusive.  There are no wearable devices to remember or unfamiliar sensors to be discarded.  Discharge from hospital could be accelerated with a KemuriSense Power Socket pre-installed.

Families and carers use the Wellbeing App for peace of mind.  At any time of day, from anywhere in the World, people can view the changes to patterns of behaviour.  There’s an option to receive alerts after more changes than usual.  They can enquire about wellbeing with full knowledge of the predictive analysis and decide on appropriate action. Some of the tragic outcomes of unattended falls are avoidable with hourly monitoring.  Additionally, it’s possible to confirm that domiciliary carers have provided drinks and meals at the time they were ordered.

Service organisations benefit from accurate data.  Sheltered housing wardens, domiciliary care providers and alarm response centres have full access to the Wellbeing Monitor and can prioritise their care calls.  Kemuri is efficient to deploy.  The portable model is operational in ten seconds with no skill required.  The fixed model can be installed and tested within 15 minutes.  There are no rules to enter because the system learns patterns of activity.  Alerts are automatically sent to response centres or users of the app.  
Current and planned activity: 
Manufacturing batches of 100 units for trials/sales to housing associations/telecare service providers. First trials are in sheltered accommodation in County Durham in conjunction with Durham University (part of EU funded Erasmus+ project)

Controlled clinical trials required to collect evidence to support the benefits claimed (reducing impact of falls). Sample sizes to account for significant number of subjects continuing to live normally without any falls requiring intervention. Access to medical records/cost of treatment/health outcomes/discharge data/subsequent care pathways required

Kemuri collects accurate lifestyle data that can be used in clinical trials of drugs dispensed to people living independently including people with cognitive impairment/physical disability not able to record times of events/ambient conditions. KemuriSense power sockets can collect data for several years, in dementia trials it may be possible to identify rates of decline & use it to modify the care regime
What is the intellectual property status of your innovation?:
Kemuri has patents pending; GB1417259.7, effective date of 30 September 2014 and PCT/GB2015/000275, International Filing Date of 30 September 2015. 

Note that the patent applies to more devices than a power socket.  It covers the internal electronics and components, which could be incorporated into any equipment consuming significant amounts of power. 

Kemuri and KemuriSense are registered trademarks.  
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Regulatory Approvals:
The KemuriSense Smart Power Socket has been tested for EMC (Electro Magnetic Compliance) and CE certification. 

The product only measures ambient conditions and does not require certification as a medical device.
Commercial information:
We are building batches of 100 for field trials with availability in January 2017. 

The projected sales shown in the table below.



The growth accelerates as more telecare resellers become customers.

Current and potential telecare users: The Strategic Society Centre undertook a major quantitative research project entitled Who uses telecare? published in 2012 to explore usage of telecare among older people in England and identify potential users of telecare. It provided a conservative estimate based on 2008 data that among the over-50s in England, there were well over 1 million telecare users. However, by mapping individuals with similar conditions, the report was able to identify around 2.5 million more individuals living alone who may be able to benefit from telecare, and potentially as many as 4.1 million with conditions that could merit the use of telecare.

Further, the report stated that around 30% to 50 % of current telecare users paid for their telecare themselves or with the help of a family member. Among private and non-privately funded telecare users, it appears there is little difference in incomes. This suggests that relatively low income is not a barrier to individuals and their families funding telecare themselves or that most users can contribute to the cost of telecare support.
The report made recommendations to policymakers to aim to boost the usage of telecare to at least double current prevalence focusing on individuals living alone. It also recommended that policymakers and the industry should focus on targeting informal carers, including both cohabiting and non-cohabiting family carers as potential beneficiaries of greater usage of telecare.

Global telecare market: The global telecare market is valued at c. £1 billion per annum and is forecast by the Deloitte Centre for Health Solutions to grow at a rate of 5% per annum from now to 2018. The factors contributing to growth and market attractiveness are related to government initiatives and funding and the public willingness and receptivity towards technological advancement. The UK is the leading market for telecare products and services, with the UK telecare market share of up to 25% of the global market. Other prominent markets for telecare in terms of ageing populations that demand such services include France, Italy and Benelux (comprising Belgium, Luxemburg and the Netherlands).

Ireland, Malta, Singapore, Hong-Kong, Malaysia and Saudi Arabia as potential overseas markets for KemuriSense®, as those territories use British standard socket outlets.
Investment activity:
Kemuri was founded by Dr Leonard Anderson, Russell Anderson and Michael Anderson in January 2014.  Together, they worked on the concept for an older person’s carer assistance solution after failing to find a suitable product and service on the market.  The Company’s activity to date has been focused on product and web-services development and has been funded from private and public sources.  Kemuri’s proof-of-concept project was successfully completed in October 2015, assisted by grants from Innovate UK; £66,734 for a Smart Grant and £5,000 for a Smart Voucher. A £2,000 prize from Kent County Council paid for the first smart power socket prototype. 

Dr Anderson has provided an unsecured director's loan facility of £100,000.

Innovate UK sponsored £5000 research with the Institute of Ageing at Newcastle University for the Ethics of Passive Monitoring.

The company raised £545,000 in a private offer via West Hill Capital.  The funds are being deployed to refine the core product infrastructure, to develop the mobile app, to recruit staff across operations and to build an online sales platform. 

Kemuri has been awarded with €100,000 as a partner in an Erasmus + project for people-centred centred design.  Our UK partner is Durham University together with others in Netherlands, Czech Republic and Slovenia

The Company is a growth business and will not be cash generative in the short term as it invests heavily in developing the business in order to generate long-term profitable business relationships.

A key requirement is to find funding for an academic study to collect evidence for the value of predictive analytics for a period of at least one year.  Grants are being sought from multiple sources.
Regional Scalability:
Smart power socket production is scalable (batches of 100-1000 p.m) in the Woking production facility (larger volumes achieved by second sourcing manufacture). The Web technology is cloud-based & can be rapidly scaled by commissioning more servers/storage at short notice. WM scale-up can be generated by raising awareness with the following:
  • Social Services Commissioners/OTs
  • GP Surgeries, Mental Health & Hospital Trusts
  • Housing Associations & Voluntary Sector eg AgeUK
  • Telecare Service Companies
  • Local media/online sales websites 
Welbeing, our telecare service partner’s clients include WM local authorities & housing associations, providing installation & call monitoring services to any new customers in the region.

As a start-up our effort is directed to delivering reliable hardware & software with small sample numbers. Our design objective is for KemuriSense power sockets to operate continuously for at least 5 years. First trials have started in County Durham housing associations.
Measures:
In co-operation with an academic research partner, we hope to achieve the following in a trial:

Quality
  • Continuous reliable operation
  • Avoidance of false alerts
  • Recognising unattended falls, strokes or other episodes that result in a carer taking action that saved time and cost for medical intervention.
  • Peace of mind achieved for families and carers
  • Identifying trends that indicate the risk of hypothermia, dehydration and malnutrition.
  • Identifying activity at unusual times of day that lead to helpful family or medical intervention 
Safety
  • Electrical safety of products after installation in kitchens.
  • Security of personal data and avoidance of data loss. 
Cost
The trial budget is £500,000.  This would include the costs of selection, installation, monitoring, service support and surveying families throughout the trial.  Note that his includes detailed data analysis, medical services, the final report and communications.
 
People
The target group for research is a cohort that has these attributes:
  • Reject pendant alarms
  • Deny declining capacity
  • Want to live independently
  • Show symptoms of dementia
  • Need daily monitoring
A percentage will be used as a control group who are not included in the Trial.  The total numbers are to agreed by the academic research partner from one of the West Midlands universities.
 
Ethics
Finding volunteer older people and their next of kin will require access to the medical records and adult social care records of older people living alone.  This will also be needed during the trial to measure the times and costs of medical treatment.  Approval by the Ethics Committee will be required.  
Adoption target:
Assuming that there are 500,000 unused pendants in the UK, there are approximately 40,000 candidates for Kemuri wellbeing monitoring in a West Midlands population of 5 million.   

500 is a reasonable target for 2017/2018 – with an possibility of growing to 10,000 in 5 years.  
Investment sought:
A total investment of £500,000 over two years would provide a trial that provides evidence for wider adoption in the Region.  For budgeting purposes, this breaks down as follows:
  • £40,000 - Project Management
  • £100,000 – Installation and Web services for 120 older people and their families
  • £50,000 – Health service costs
  • £250,000 – Academic research costs
  • £60,000 – Kemuri cost to support the trial. 
The findings should be applicable throughout the UK. 

The objective is to obtain SBRI funding for the project.  
Read more
Hide details

Created by

Share and Follow